Apixaban to prevent stroke in atrial fibrillation and kidney failure
Part of Brain & nervous system, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign a consent form (or have a legal representative sign it).
- You are age 18 or older.
- You have atrial fibrillation or atrial flutter that keeps coming back, lasts, or is ongoing.
- Your kidney function is very low (eGFR under 20) for long enough, or you are already on chronic dialysis.
- Your stroke-risk score is high enough that a blood thinner is usually recommended.
- If you can become pregnant, you must test negative and use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether apixaban, a blood thinner, works well for people with atrial fibrillation who also have heart or circulation conditions. It uses a smartphone app to help track your treatment.
This trial compares two blood thinners, apixaban and warfarin, in people on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). The goal is to see which one works better and is safer for preventing strokes.
This study compares two ways to manage atrial fibrillation (an irregular heartbeat) in people on dialysis. One approach uses a blood thinner called apixaban, and the other does not use blood thinners. The goal is to see which approach better prevents strokes and bleeding.
This study checks how apixaban (a blood thinner) moves through the body in people who are on peritoneal dialysis and have non-valvular atrial fibrillation. It may help confirm the safest and most effective dosing for patients who have little or no remaining kidney function.
This trial compares two types of blood thinners (vitamin K antagonists and factor Xa inhibitors) versus no blood thinner in people with atrial fibrillation who are on dialysis or have very advanced kidney disease. It aims to see which option is safest and most effective for preventing strokes and bleeds.
This trial tests whether taking apixaban alone is as safe and effective as taking apixaban plus clopidogrel for people who have had a stroke due to atrial fibrillation and also have hardened arteries in the brain or neck. It aims to find the best way to prevent another stroke.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.